Premium
Indoleamine 2,3‐dioxygenase ( IDO ) Activity in Placental Compartments of Renal‐Transplanted Pregnant Women
Author(s) -
do Prado Karen Matias,
CorreaSilva Simone,
Oliveira Leandro Gustavo,
Camara Niels Olsen Saraiva,
Ono Érica,
Sandri Silvana,
Tourino Melissa Cavalheiro,
Campa Ana,
Sá Lima Larissa,
Scavone Cristoforo,
Bevilacqua Estela
Publication year - 2014
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12233
Subject(s) - indoleamine 2,3 dioxygenase , decidua , medicine , fetus , pregnancy , endocrinology , placenta , immunology , biology , tryptophan , biochemistry , genetics , amino acid
Problem Immunosuppressive drugs change gestational IDO activity at the maternal–fetal interface. Method of Study Analysis of placental IDO expression and activity, interferon gamma ( IFN ‐γ), and IL ‐10 expression and NF kB activity in renal transplant recipient women under immunosuppressive treatment. Results We demonstrated a significant reduction in IDO activity ( P = 0.0275) and expression ( P = 0.026) and in NF kB activity ( P = 0.0176) in the villous region of renal transplanted mother. These findings did not correlate with the higher serum levels of kynurenine ( P = 0.002). In the decidual compartment, IDO was immunolocalized mainly on the extravillous cytotrophoblast but did not show significant differences among the experimental groups; kynurenine was significantly higher ( P = 0.036) and was inversely proportional to the decidual IFN ‐γ profile ( P = 0.0433). No change was seen in IL ‐10 levels. NF kB activity was significantly higher in decidual compartment correlating with the higher IDO activity and suggesting that in immunosuppressant pregnancy, IDO activity and expression remain regulated by NF kB. Conclusion The increased IDO activity in decidua may indicate an attempt to offset the low expression. These findings call attention to the relevance of IDO activity at the maternal interface in pregnant transplant recipients, likely modulated by immunosuppressive agents and associated with a high risk of associated gestational disorders.